The vasodilatory effect of intra-cisternal infusion of magnesium sulfate solution was evaluated in 10 patients with symptomatic vasospasm after aneurysmal subarachnoid hemorrhage (SAH) who underwent early clipping surgery. Cisternal drainage was installed in the prepontine and/or sylvian fissures. Carotid angiography was performed immediately after the onset of symptomatic vasospasm, then intracisternal infusion of 15 mmol/l magnesium sulfate in Ringer solution was started at 20 ml/hr and continued until day 14. Irrigation was performed from the cisternal tube (inlet) to the spinal drainage (outlet). The cerebrospinal fluid magnesium ion concentration (1.2 ± 0.2 mEq/l) significantly increased after the infusion therapy (6.0 ± 1.7 mEq/l, p º 0.001). Repeat angiography showed vasodilatory effect on the spastic cerebral arteries at 3 hours after the infusion, especially in the arteries near to the site of cisternal drainage placement. The magnesium infusion also caused decreased mean arterial blood velocity in the spastic arteries in 6 of the 7 measured patients (162 ± 38 cm/sec to 114 ± 42 cm/sec, p º 0.001). Finally, 5 of the 10 patients achieved good recovery, 1 patient had moderate disability, 1 patient became severely disabled due to meningitis, and 3 patients were vegetative or dead, due to failure of magnesium irrigation in 1 patient and advanced age in the other 2 (more than 80 years old). This preliminary study indicates that intra-cisternal infusion of magnesium sulfate solution has vasodilatory effect on the spastic cerebral arteries after aneurysmal SAH.
Introduction
Delayed cerebral vasospasm remains a common cause of morbidity and mortality despite advances in microsurgical or endovascular treatments of aneurysmal subarachnoid hemorrhage (SAH). Onethird of the patients with symptomatic vasospasm die and another one-third suffer permanent neurological deficit. 3, 10) Various prophylactic strategies against cerebral vasospasm have been advocated, such as intra-oral intake of calcium blocker (nimodipine), 1) nicardipine prolonged-release implant, 6) rhokinase inhibitor (fasudil hydrochloride), 22) cisternal irrigation with urokinase or tissue plasminogen activator, 8, 12) and cisternal irrigation with milrinone. 2) However, after the onset of symptomatic vasospasm, only a few therapies are available, such as hypertensive-hypervolemic-hemodilution (triple-H) therapy, 18) intra-arterial injection of papaverin, 5) and transluminal balloon angioplasty. 15) Therefore, a new therapeutic modality to dilate the spastic cerebral arteries during symptomatic vasospasm is needed.
Pilot clinical studies have demonstrated the safety and efficacy of intravenous magnesium therapy for SAH. 24, 26) However, recent prospective studies of continuous intravenous administration of magnesium sulfate in patients with aneurysmal SAH failed to show any vasodilatory effect on vasospasm detected by angiography and transcranial Doppler ultrasonography. 20, 23) The blood-brain barrier is relatively impermeable to magnesium ion (Mg 2＋ ), so increased blood concentration of Mg 2＋ may not affect
the spastic cerebral arteries. 21) In contrast, in vitro studies clearly show that increased extracellular Mg 2＋ concentration definitely causes vasodilation of both normal and contracted cerebral vessels in the presence of vasospasm-inducing agents. 11, 17) Therefore, intra-cisternal administration of Mg 2＋ is expected to reverse delayed cerebral vasospasm. Recently, we showed that intra-cisternal infusion of Mg 2＋ solution improved reduced cerebral blood flow (CBF) induced by experimental SAH in the rat. 14) Furthermore, we demonstrated the vasodilatory effect of intra-cisternal injection of Mg 2＋ solution on spastic cerebral arteries in the dog model of SAH. 13) The present study examined the vasodilatory effect of intra-cisternal infusion of magnesium sulfate solution on the spastic cerebral arteries of patients who developed symptomatic vasospasm after aneurysmal SAH.
Materials and Methods
The clinical trial protocol was reviewed and approved by Juntendo University Shizuoka Hospital ethics committee (#073). Informed consent for this protocol was obtained from each patient or legally authorized representative.
Intra-cisternal infusion of magnesium sulfate solution was performed in 10 patents with aneurysmal SAH who underwent direct clipping surgery within 24 hours of onset, and with computed tomography (CT) findings classified as Fisher group 4) 3 or 4. A cisternal drainage tube was placed in the prepontine cistern after opening of the Liliequist membrane, and an additional drainage tube in the sylvian fissure because of thick SAH in the sylvian fissure in Case 7. A spinal drainage tube was placed in the lumber spine immediately after the clipping surgery. Fasudil hydrochloride (90 mg/day, 14 days) was administered to all patients but not triple-H therapy.
The diagnosis of symptomatic vasospasm was based on reduced level of consciousness (more than 2 points lower on the Glasgow Coma Scale) and/or focal neurological deficits in the absence of other potential causes. Immediately after the onset of symptomatic vasospasm, if CT detected no low density area due to vasospasm, a 4F sheath catheter was placed in the femoral artery and carotid angiography was performed on the operated side. After the angiography, 10 ml of 15 mmol/l magnesium sulfate in Ringer solution (Na
109 mEq/l, lactate 28 mEq/l) was administered through the cisternal catheter followed by clamping for 1 hour. Continuous infusion of 15 mmol/l magnesium sulfate solution at 20 ml/hr was started and continued until day 14. Irrigation was performed through the cisternal to spinal drainage. The cisternal tube and the pressure control system at 15 cmH 2 O were connected by a T-connector for safe irrigation. Three hours after the start of intra-cisternal infusion of magnesium sulfate, carotid angiography was repeated through the same femoral sheath catheter.
The arterial diameter before and after the intracisternal infusion of magnesium sulfate solution was measured and the percentage increase calculated by a radiological technician unaware of the details of the clinical protocol. The arterial diameters were measured at the narrowest points in each arterial segment (C 1 or C 2 segment of the internal carotid artery, M 1 and M 2 segments of the middle cerebral artery, A 1 and A 2 segments of the anterior cerebral artery, and the posterior communicating artery). The cerebrospinal fluid (CSF) and serum Mg 2＋ concentrations were monitored before and after the intracisternal infusion of magnesium sulfate solution using ion-selective electrodes (StatProfile CCX; NOVA Biomedical, Boston, Mass., U.S.A.). Transcranial Doppler ultrasonography was performed to measure the mean blood flow velocity in the middle cerebral artery on the onset day of symptomatic vasospasm and the next day in 7 patients. The significance of differences was analyzed by the paired t-test using SPSS 7.5.1 J for Windows (SPSS Japan Inc., Tokyo). P values º 0.05 were considered statistically significant. Table 1 summarizes the characteristics and outcomes of the 10 patients with symptomatic vasospasm treated by intra-cisternal infusion of magnesium sulfate solution. Table 2 shows the percentage increase in spastic arterial diameter at 3 hours after infusion. The duration of intra-cisternal infusion of magnesium sulfate solution ranged from 4 to 9 days (mean 6.7 ± 1.6 days). CSF Mg 2＋ concentration before infusion was 1.2 ± 0.2 mEq/l and significantly increased to 6.0 ± 1.7 mEq/l after infusion (p º 0.001), except in Case 8 who did not show any increase in CSF Mg 2＋ up to day 14. The Mg 2＋ concentration in the spinal CSF became stable at 2 days after starting the irrigation, so we took the CSF Mg 2＋ concentration at 2 days after the irrigation as the representative value. The pre-and postinfusion serum Mg 2＋ concentrations were 0.8 ± 0.1 and 0.9 ± 0.1 mEq/l, respectively, and were not significantly different. All patients except for Case 8, who did not respond to magnesium infusion, showed vasodilatory effect on the spastic cerebral arteries at Intra-cisternal Magnesium Infusion 3 hours after the intra-cisternal infusion of magnesium sulfate solution. The posterior communicating artery was the most commonly dilated artery (40 ± 25%) because of its close location to the cisternal tube placement (Fig. 1 ). Case 7 who had the cisternal tube in the sylvian fissure showed prominent dilation of the M 1 and M 2 segments (Fig. 2) . The mean flow velocity in the middle cerebral artery at the onset of symptomatic vasospasm (162 ± 38 cm/sec) decreased significantly on the day after the intracisternal infusion (114 ± 42 cm/sec, p º 0.001), except in Case 8. Case 8 showed a further increase in mean flow velocity, and subsequently developed cerebral infarct in the middle cerebral artery territory on CT resulting in vegetative state. The angiographic vasodilatory effects appeared immediately after starting the magnesium irrigation therapy, whereas the neurological symptoms showed gradual resolution in patients without severe infarction on CT. Complications of magnesium cisternal irrigation therapy induced meningitis in one patient, and respiratory suppression in two patients who completely recovered after the irrigation. The cause of the respiratory suppression could not be clarified in this limited study. The outcome was evaluated at 6 months postoperatively. Five patients had good recovery, 1 patient had moderate disability, 1 patient had severe disability due to meningitis, 2 patients developed vegetative state, and 1 patient died. Cases 9 and 10 aged more than 80 years old had cerebral infarcts on CT which resulted in vegetative state or death despite the increased CSF Mg 2＋ concentration.
Results

Discussion
Mg 2＋ has a vasodilation effect mediated through blocking of Ca 2＋ influx and competitive inhibition of Ca 2＋ binding at the calmodulin sites which affect the myosin light chain kinase active form in the smooth muscles of cerebral blood vessels. 25) Mg 2＋ also attenuates the effects on the cerebral arteries of endothelin-1 and oxyhemoglobin, which are considered to be important potent vasoconstrictors after SAH. 7, 11) The present study demonstrated that intra-cisternal infusion of magnesium sulfate solution has a vasodilatory effect on the spastic cerebral arteries of patients with symptomatic vasospasm following aneurysmal SAH. The effect of magnesium infusion was most prominent in the arteries near to the cisternal drainage placement because the repeated angiography was performed shortly after the start of infusion (3 hours) . This finding suggests the importance of the location of the cisternal tube that is used for magnesium infusion. The cisternal tube should be placed in the cistern containing the thick SAH blood clot.
The present study used 15 mmol/l magnesium sulfate in Ringer solution. The optimal concentration for the infusion is not clear. Recently, cisternal irrigation with 3 mEq/l Mg 2＋ and 4 mg/ml ascorbic acid was reported to prevent the occurrence of cerebral vasospasm after aneurysmal SAH. 19) Our preclinical study demonstrated that intra-cisternal infusion of 10 mmol/l magnesium sulfate solution improved the CBF reduced by experimental SAH in the rat. 13, 21) The optimal concentration may be 10 mmol/l magnesium sulfate solution. The vasodilatory effect of magnesium infusion therapy may depend on maintaining the CSF Mg 2＋ concentration at 3 mEq/l more than the concentration of the infusate. 13, 19) Further study is needed to settle this issue.
Magnesium infusion failed to increase the CSF Mg 2＋ concentration in one of our patients. In this series, the cisternal tube was connected to the pressure control system at 15 cmH 2 O by a T-connector. The cisternal tube in Case 8 may have been obstructed, thus preventing flow of magnesium infusate into the cerebral cisterns. This patient developed cerebral infarct resulting in vegetative state. We have to develop a more effective and safe intracisternal infusion system. Our two patients aged more than 80 years old did not respond to the magnesium infusion therapy, and developed cerebral infarcts resulting in poor outcomes. Elderly patients may suffer other conditions such as thromboembolism and cortical spreading depression rather than cerebral vasospasm of the large vessels. 9, 16) Milrinone irrigation and prolonged-release nicardipine implant in the cerebral cisterns are also potent methods to dilate the spastic cerebral arteries after SAH. 2, 6) However, Mg 2＋ is a physiological component of the CSF, and the magnesium concentration in the infusate can be controlled by monitoring the CSF Mg 2＋ concentration.
This preliminary clinical study included a limited number of patients, so we cannot conclude whether the vasodilatory effect of intra-cisternal magnesium infusion therapy is related to the improvement of the clinical outcome. Further study is needed to assess the optimal concentration of magnesium sulfate, optimal start timing and duration of the infusion, location of the cisternal drainage placement, infusion system, and the neurotoxicity of intra-cisternal injection. However, this study does indicate that intracisternal injection of magnesium sulfate is a promising treatment to ameliorate cerebral vasospasm in patients with SAH.
Fisher Scale proposed by Zervas and Ogilvy 2) is more accurate than the Fisher Scale for defining and predicting patients with potential risk of vasospasm. Continuous injection of magnesium sulfate may cause higher ICP. The authors infused the solution with the pressure of 15 cmH 2 O, so how to treat the patients when the ICP is beyond this level? Therefore, a prospective randomized controlled trial should be carried out before the conclusion that intra-cisternal infusion of magnesium sulfate ameliorates cerebral vasospasm in SAH patients is made.
